Want to see DTIL full AI Analyst Report?
Top Page
Precision BioSciences
(NASDAQ:DTIL)
Select Model
Select Model
Rating:43Neutral
Price Target:
$6.50
▼(-23.44% Downside)
Action:Reiterated
Date:10/17/26
DTIL scores low primarily due to weak financial performance (continued losses and significant cash burn) and bearish technicals (trading below key moving averages with negative MACD). Corporate events provide a partial offset via positive clinical progress and leadership updates, while valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Clinical and Regulatory Progress
Dosing the first patient moves Precision BioSciences’ ARCUS platform into clinical testing for a major genetic disease. The program’s regulatory designations and broad exon 45-55 target population could support development momentum and future partnering potential.
Negative Factors
Substantial Cash Burn
Persistent operating and free-cash-flow deficits show that the company is consuming substantial cash to fund its operations and development programs. If this burn continues, Precision BioSciences may become increasingly reliant on external capital, limiting strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical and Regulatory Progress
Dosing the first patient moves Precision BioSciences’ ARCUS platform into clinical testing for a major genetic disease. The program’s regulatory designations and broad exon 45-55 target population could support development momentum and future partnering potential.
Read all positive factors
Precision BioSciences (DTIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$181.07M
Dividend YieldN/A
Average Volume (3M)261.52K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth3472.96%
EPS Growth67.74%
CountryUS
Employees67
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.79
Shares Outstanding27,601,555
10 Day Avg. Volume254,497
30 Day Avg. Volume261,520
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.58
Price to Sales (P/S)1.56
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit3.19
Enterprise Value/Ebitda-2.89
Forecast
1Y Price Target
$45.00Price Target Upside430.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.59
Revenue Forecast (FY)$13.43M
Precision BioSciences Business Overview & Revenue Model
Company Description
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary gen...
How the Company Makes Money
Precision BioSciences primarily generates revenue through collaboration-related arrangements rather than product sales (to the extent commercial products are not available or not material). Key revenue streams typically include: (1) upfront paymen...
Precision BioSciences Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.05M | 34.26M | 68.70M | 48.73M | 25.10M | 115.53M |
| Gross Profit | 45.05M | 34.26M | 68.70M | 48.73M | 25.10M | 115.53M |
| EBITDA | -49.70M | -42.43M | 13.53M | -32.04M | -62.79M | -20.27M |
| Net Income | -52.73M | -45.72M | 7.17M | -61.32M | -111.64M | -30.60M |
Balance Sheet | ||||||
| Total Assets | 125.92M | 154.42M | 136.39M | 159.78M | 238.17M | 211.50M |
| Cash, Cash Equivalents and Short-Term Investments | 87.55M | 115.58M | 86.31M | 116.68M | 189.58M | 143.66M |
| Total Debt | 28.10M | 28.81M | 30.05M | 31.27M | 24.96M | 9.11M |
| Total Liabilities | 80.63M | 62.17M | 80.00M | 140.92M | 177.74M | 120.33M |
| Stockholders Equity | 45.29M | 92.25M | 56.39M | 18.86M | 60.43M | 91.17M |
Cash Flow | ||||||
| Free Cash Flow | -51.95M | -65.93M | -58.70M | -86.39M | -49.07M | -16.66M |
| Operating Cash Flow | -51.90M | -65.84M | -58.45M | -84.11M | -45.75M | -10.85M |
| Investing Cash Flow | -421.00K | -634.00K | -215.00K | 5.83M | -3.32M | -5.80M |
| Financing Cash Flow | 79.92M | 95.16M | 50.45M | 5.39M | 94.98M | 70.52M |
Precision BioSciences Technical Analysis
Positive
8.49
Price Trends
7.03
Negative
7.19
Negative
6.44
Positive
Market Momentum
-0.15
Negative
53.72
Neutral
63.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Positive. The current price of 8.49 is above the 20-day moving average (MA) of 6.29, above the 50-day MA of 7.03, and above the 200-day MA of 6.44, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 53.72 is Neutral, neither overbought nor oversold. The STOCH value of 63.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DTIL.
Precision BioSciences Risk Analysis
Precision BioSciences disclosed 75 risk factors in its most recent earnings report. Precision BioSciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Precision BioSciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $42.03M | -0.39 | -74.90% | <0.01% | ― | 44.73% | |
48 Neutral | $76.92M | -0.97 | -70.14% | ― | ― | 16.04% | |
45 Neutral | $46.88M | -0.78 | -38.99% | ― | ― | 31.98% | |
44 Neutral | $546.93M | -5.33 | -38.46% | ― | -87.03% | -179.91% | |
43 Neutral | $181.07M | -2.41 | -91.60% | ― | 3472.96% | 67.74% |
* Healthcare Sector Average
DTIL
Precision BioSciences
6.71
-0.22
-3.17%
CTMX
CytomX Therapeutics
2.40
-0.90
-27.27%
ACET
Adicet Bio
4.49
-9.29
-67.41%
IMA
ImageneBio
4.09
-3.30
-44.72%
ACRV
Acrivon Therapeutics, Inc.
1.83
-0.18
-8.75%
Precision BioSciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Begins First DMD Gene-Editing Trial
Positive
Aug 24, 2026
On August 24, 2026, Precision BioSciences announced that it had dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD at Arkansas Children’s Hospital, marking the first clinical gene-editing program for Duchenne ...
Business Operations and StrategyExecutive/Board Changes
Precision BioSciences Announces Key Executive Leadership Changes
Positive
Jul 27, 2026
On July 23, 2026, Precision BioSciences’ board approved a series of senior leadership changes effective August 1, 2026, including promoting Chief Financial Officer Alex Kelly to the newly created role of Chief Operating Officer to oversee ke...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.